Background:
Apatinib, an oral VEGFR2 inhibitor, has been approved as third line treatment for metastatic gastric cancer in China. The aim of this study was to evaluate the efficacy and safety of apatinib, in the treatment of refractory metastatic colorectal cancer patients who failed from two or more lines of chemotherapy.
Methods:
In this open-label, single-arm, phase II study, patients were treated with apatinib in daily dose of 500 mg, po, in the third -or more line setting. Capture sequencing was dynamically performed to identify somatic variants in circulating tumor DNA (ctDNA) with a panel of 1021 cancer related genes.The primary endpoint was progression-free-survival (PFS) and the tumor response was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. Interim analyses was applied as predefined.
Results:
From June 01, 2016 to December 31, 2017, 26 patients were enrolled. The median PFS of the whole group was 3.9m (95% CI: 2.1-5.4). Patients with PS 0-1 had longer PFS than those with PS 2 (4.17m vs 1.93m, p = 0.0014). Patients without iver metastasis also had longer PFS than those who had live metastasis ( 5.87m vs 3.33m, p = 0.0274). Median overall survival was not reached. 10-month survival rate was 55%. The common side effects of apatinib were hypertension, hand-foot syndrome, proteinuria and diarrhea. The incidence for grade 3-4 hypertension, hand-foot syndrome, proteinuria and diarrhea were 76.92%, 11.54%, 73.08%, and23.08%, respectively. All of the patients received dose reduction due to adverse effect. Results of capture sequencing showed APC, TP53 and KRAS were most frequently mutant genes. Patients with high tumor mutation burden (TMB) in baseline blood had a trend of prolonged overall survival than those with low TMB (p = 0.077). The molecular tumor burden from ctDNA increased before the radiographic assessment in 10 patients.
Conclusions:
Apatinib monotherapy showed promising efficiency for refractory colorectal cancer patients, especially in patients with PS 0-1 or no liver metastasis. TMB is a potential prognostic biomarker. In addition, tumor molecular burden may be a predictor in serial monitoring of tumor load. 
Background:
Anti-angiogenic therapy combined with chemotherapy could improve the outcome of platinum-resistant ovarian cancer. Apatinib is an oral tyrosine kinase inhibitor which selectively inhibits VEGFR2. We assessed the efficacy and safety of combination of apatinib and oral etoposide, which has the advantage of home administration without an infusion pump and hospitalization, in patients with platinum-resistant or platinum-refractory ovarian cancer.
Methods:
In this phase 2, single-arm, open-label study, we included patients aged 18-70 years with platinumresistant or platinum-refractory ovarian cancer. Patients received oral etoposide 50 mg on days 1 to 14 in a 21-day cycle for a maximum of six cycles. In addition to the chemotherapy, apatinib 500 mg was administered orally once daily. The primary endpoint was objective response rate by RECIST version 1.1. A Simon two-stage design was employed. This study was registered with ClinicalTrials.gov, number NCT02867956.
Results:
Between Aug 10, 2016 and Nov 9, 2017, 35 patients were enrolled. At data cutoff (Dec 31, 2017), 20 (57.1%) of 35 patients had discontinued study, and 15 (42.9%) patients remained on treatment. The reasons for treatment discontinuation included disease progression (n = 10), adverse events (n = 4), consent withdrawal (n = 2), lost of follow-up (n = 2), and others (n = 2). Objective responses were achieved in 19 (54.3%; 95% CI: 36.6-71.2) of 35 patients and disease control was obtained in 30 (85.7%; 95% CI: 69.7-95.2) patients. The median progression-free survival was 8.1 months (95% CI: 2.8-13.4). The most common grade 3 or 4 adverse events were neutropenia (41.2%), fatigue (32.4%), anaemia (29.4%), and mucositis (23.5%). No treatment-related death was recorded. All of the adverse events were manageable. Dose reductions occurred in 82.4% of the patients for apatinib and 76.5% of the patients for oral etoposide.
Conclusions:
The combination of apatinib with oral etoposide shows promising activities and manageable toxicities in patients with platinum resistant or refractory recurrent ovarian cancer, and warrants further study in phase 
Background:
Ahead-G201, a multicenter Phase IV study, is conducting to evaluate apatinib as third-line or beyond therapy in a routine practice setting of gastric cancer patients (pts).
Methods:
This analysis was undertaken to evaluate the non-hematological adverse events (AEs), and to explore their potential associations with survival.
Results:
This analysis was based on 1468 pts as of 12/21/2017. The most common non-hematological AEs were hypertension (HTN; 22.8%), proteinuria (PTN; 18.1%), fatigue (16.7%), diarrhea (11.9%) and hand-foot-skin reaction (HFSR; 9.7%), irrespective of the relationship with medication. They were not correlated with progression free survival (PFS); however, pts with diarrhea or HFSR had a statistically longer overall survival (OS) (8.41 vs. 6.14 mos, p= 0.0048; 8.31 vs. 5.98 mos, p< 0.0001) (Table) . After adjusting for baseline characteristics and treatment dose, presence of HFSR was an independent predictor for prolonged OS (HR: 0.62 [95%CI, ). Besides, we assessed hepatotoxicity and cardiotoxicity in pts.
269 (18.3%) pts who developed hepatotoxicity had a statistically longer PFS (4.70 vs. 3.38 mos; p= 0.0458).
A low incidence of cardiotoxicity (2.1%) was detected, and it was not related to survival.
Conclusions:
Occurrence of HFSR could be an effective prognostic factor for OS in apatinib-treated gastric cancer pts, whereas hepatotoxicity might predict PFS. Clinical trial information: NCT02426034
Relationship between non-hematological AEs and survival. 
Background:
A phase 1 (P1) study to assess the safety and efficacy of combination of S, a fully human IgG4 monoclonal antibody against PD-1 with PD-L1/PD-L2 plus Apatinib (A), a VEGFR2 inhibitor in patients (pts) with advanced HCC, GC, EGJ cancer.
Methods:
In P 1a dose escalation, pts received A (125, 250, 500mg, QD, 5 pts per cohort) and S (200 mg, Q2W) until unacceptable toxicity, disease progression. In phase 1b cohort expansion, pts received A at recommended P2 dose (RP2D) + S (200 mg, Q2W). Response was evaluated by RECIST v1.1.
Results:
At the cut-off data (Feb. 2. 2018), 42 pts (P 1a, n = 15; P 1b, n = 27) were enrolled. Median prior lines of therapy in HCC and GC were 1 and 2, respectively. In P1a stage, 3 DLTs (all grade 3 pneumonia) were observed in A 500mg cohort. The RP2D was A 250mg + S. In P 1b stage, the median treatment duration was 19 wks (range, 2-57 wks). 19 pts (58%) had ≥ grade 3 treatment-related adverse events (TRAEs). The ≥10% grade 3 TRAEs were hypertension (18%), increased AST (15%) and ALT (12%). These AEs were manageable, only 1 pt discontinued treatment due to TR grade 3 hyperbilirubinemia. There were no TRdeaths. The ORR and DCR in 36 evaluable pts in all 3 cohorts were 30.6% (n = 11) and 83.3% (n = 30), respectively. All 11 responses occurred in A 125mg (n = 1) and 250mg (n = 10) cohorts. Among 18 HCC pts (14 evaluable: A 125mg cohort, n = 4; A 250mg cohort, n = 9, A 500mg cohort, n = 1), all infected with HBV. The ORR and DCR were 50.0% and 85.7%, respectively. Notably, 2 pts in A 125mg cohort had initial SD at best response, and achieved PR after escalating A dose to 250 mg, therefore the ORR at A 250 mg dose level was 54.5% (6/11). The median progression-free survival (PFS) was not reached. All 7 pts with PR were still on treatment, 5 lasted for 47 weeks+. Of 24 GC or EGJ cancer pts (22 evaluable: A cohort, 250mg n = 20; 500mg, n = 2), the ORR in A 250mg cohort was 20.0% and DCR was 80.0%. The median PFS was 3.0 months.
Conclusions:
S + A at RP2D demonstrated manageable toxicity in HCC, GC or EGJ cancer pts. 
Background:
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced steosarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. We aimed to assess the activity of apatinib in patients with locally advanced or multiple metastatic high-grade osteosarcoma progressing after standard treatment.
Methods:
This non-randomised phase 2 trial was done in Peking University People's Hospital. We enrolled participants (≥16 years) with relapsed or unresectable osteosarcoma progressing after standard treatment (methotrexate, cisplatin, doxorubicin, and ifosfamide). Participants received 750 mg or 500mg apatinib according to body surface area (BSA) once daily until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (CR+PR at least 3 months according to RECIST 1.1) and PFS at 4 months. All analyses were intention-to-treat.
Results:
37 participant were enrolled between March 17th, 2016 and June 9th, 2017. Until final follow-up, the objective response rate (CR+PR at least 3 m) was 56.76% (21/37). And the 4-m PFS rate was 52% (95% CI 32%-68%). However 9/37 (24.32%) patients was progression free at 6 months. Median PFS and OS were 4.44 (95% CI 3.12-7.08) and 8.77 (95% CI 6.73-16.70) months, respectively. Toxic effects led to dose reductions, or interruptions in a total of 25/37 (67.57%) patients. The most common grade 3-4 adverse events were pneumothorax in 5 (13.51%) patients, wound dehiscence in 4 (10.81%), abdominal cramps in 3 (8.11%), hypokalemia in 2 (5.41%) and bilirubin increase, proteinuria, hypertriglyceridaemia, hand-foot skin reaction and anemia each in one (2.70%). No other serious adverse events were reported during the trial. There were no treatment-related deaths.
Conclusions:
Apatinib was a sensitive drug for advanced osteosarcoma with high response rate after failure of 
